dr reddy's glp-1 drugs portfolio 2025 GLP 1 Drug Biosimilar Market Size and Growth Analysis 2026 to 2035 Top 10 Global Leaders in
Description
It targets both the GLP-1 and GIP receptors
[DOI] [PMC free article] [PubMed] [Google Scholar] 244.Mozaffarian D., Callahan E.A., Glickman D., Maitin-Shepard M
VLDL, very low density lipoprotein
doi: 10.1017/s000711452000224x
Beyond obesity and type 2 diabetes, the therapeutic potential of GLP-1 RAs extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease, and substance abuse disorders
